$21.19
1.35% yesterday
Nasdaq, Nov 25, 10:05 pm CET
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Catalyst Pharmaceuticals, Inc. Stock price

$21.19
-0.27 1.26% 1M
+5.32 33.52% 6M
+4.38 26.06% YTD
+7.09 50.28% 1Y
+13.81 187.13% 3Y
+16.70 371.94% 5Y
+18.46 676.19% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.29 1.35%
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Key metrics

Market capitalization $2.53b
Enterprise Value $2.09b
P/E (TTM) P/E ratio 18.08
EV/FCF (TTM) EV/FCF 11.11
EV/Sales (TTM) EV/Sales 4.54
P/S ratio (TTM) P/S ratio 5.49
P/B ratio (TTM) P/B ratio 3.82
Revenue growth (TTM) Revenue growth 32.17%
Revenue (TTM) Revenue $460.48m
EBIT (operating result TTM) EBIT $173.97m
Free Cash Flow (TTM) Free Cash Flow $188.02m
Cash position $442.33m
EPS (TTM) EPS $1.17
P/E forward 17.39
P/S forward 5.23
EV/Sales forward 4.32
Short interest 6.25%
Show more

Is Catalyst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Catalyst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Catalyst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
460 460
32% 32%
100%
- Direct Costs 100 100
41% 41%
22%
360 360
30% 30%
78%
- Selling and Administrative Expenses 138 138
69% 69%
30%
- Research and Development Expense 11 11
89% 89%
2%
212 212
111% 111%
46%
- Depreciation and Amortization 38 38
53% 53%
8%
EBIT (Operating Income) EBIT 174 174
129% 129%
38%
Net Profit 143 143
130% 130%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 23 hours ago
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution
Neutral
Investors Business Daily
4 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
GlobeNewsWire
7 days ago
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other mem...
More Catalyst Pharmaceuticals, Inc. News

Company Profile

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Head office United States
CEO Richard Daly
Employees 167
Founded 2002
Website www.catalystpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today